A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Summary

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmonary disease (COPD) who have completed the 52-week placebo-controlled treatment period in parent studies GB43311 or GB44332.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Chronic Obstructive Pulmonary Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

40 to 90 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Hoffmann-La Roche

Last updated on ClinicalTrials.gov

November 12, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites